厄洛替尼治疗化疗失败的晚期肺癌的临床研究  

Erlotinib in the treatment of advanced none small cell lung cancer patients who failed to respond previous chemptherapy

作　　者：孙玉蓓[1] 王勇[1] 胡冰[1] 江丰收[1] 

机构地区：[1]安徽医科大学附属省立医院肿瘤内科,安徽合肥230001

出　　处：《临床肺科杂志》2010年第7期980-981,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨厄洛替尼治疗化疗失败的晚期非小细胞肺癌(NSCLC)患者的临床疗效和毒副反应。方法 43例经化疗失败的晚期NSCLC患者每日口服厄洛替尼150mg治疗,直至病情进展或患者不能耐受毒副反应时停药,对临床疗效、无疾病进展时间和毒副反应等进行分析。结果全组43例患者中PR14例,占32.6%;SD12例,占27.9%;PD17例,占39.5%;疾病控制率(CR+PR+SD)为60.5%。常见毒副反应为皮疹、腹泻。结论厄洛替尼治疗化疗失败的晚期NSCLC有一定疗效,毒副反应轻。Objective To evaluate the efficacy and toxicity of erlotinib in patients with advanced none small cell lung cancer（NSCLC）who failed to respond previous chemtherapy.Methods Forty-three patients with advanced NSCLC previously treated with chemotherapy received erlotinib orally once daily until disease progression or development of intolerable toxic reaction.Response rate,progression free survival and toxicity profile were analyzed.Results.Among the forty-three patients,partial response accounted for 32.6%;stable disease accounted for 27.9%;disease control rate was 60.5%.The common adverse effects were rash and diarrhea.Conclusion Erlotinib has significant antitumor activity in advanced NSCLC who have previously failed in chemotherapy.It′s adverse effects are generally tolerable.

关 键 词：非小细胞肺癌 表皮生长因子受体 厄洛替尼 

分 类 号：R734.2[医药卫生—肿瘤]